GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Institutional Ownership

Kancera AB (OSTO:KAN) Institutional Ownership : 0.02% (As of Apr. 30, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kancera AB's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kancera AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kancera AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Kancera AB Institutional Ownership Historical Data

The historical data trend for Kancera AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Institutional Ownership Chart

Kancera AB Historical Data

The historical data trend for Kancera AB can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02

Kancera AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Kancera AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Institutional Ownership
Comparable Companies
NGM:GTAB B XSAT:ABERA OSTO:ALZ OSTO:ACTI XSAT:CURAS XSAT:BIOWKS OSTO:MVIR OSTO:NICA OSTO:ANNX OSTO:PILA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48
Website
http://www.kancera.com
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines